SuperworthSunshine Biopharma EPS SBFM
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2025
- −$35.10
- Latest quarter, Q2 FY25
- −$8.20
- Fiscal year 2024
- −$857.30
Sunshine Biopharma's earnings per share was −$35.10 over the twelve months to Jun 30, 2025.
In its latest quarter, Q2 FY25, it was −$8.20.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2024 | −$857.30 | n/a |
| FY2023 | −$3053.90 | n/a |
| FY2022 | −$28000.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY25 | −$8.20 | n/a | −$35.10 | |
| Q1 FY25 | −$4.40 | n/a | −$461.70 | |
| Q4 FY24 | −$13.10 | n/a | −$857.30 | |
| Q3 FY24 | −$9.40 | n/a | −$1844.20 | |
| Q2 FY24 | −$434.80 | n/a | −$2342.00 | |
| Q1 FY24 | −$400.00 | n/a | −$1907.90 | |
| Q4 FY23 | −$1000.00 | n/a | −$3053.90 | |
| Q3 FY23 | −$507.20 | n/a | −$23253.90 | |
| Q2 FY23 | −$0.70 | n/a | −$24346.70 | |
| Q1 FY23 | −$1546.00 | n/a | −$24946.00 | |
| Q4 FY22 | −$21200.00 | n/a | −$28000.00 | |
| Q3 FY22 | −$1600.00 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Sunshine Biopharma's size, closest first, today.
| Company | EPS, 12 months |
|---|---|
| SBFMSunshine Biopharma | n/m |
| DCOYDecoy Therapeutics | n/m |
| JAGXJaguar Health | −$6051.75 |
| LABTLakewood-Amedex Biotherapeutics | n/m |
| NXTSNexentis Technologies | n/m |
| VBIOValion Bio | n/m |
| ARTLArtelo Biosciences | −$207.09 |
| LNAILunai Bioworks | n/m |
| GNPXGenprex | n/m |
| GOVXGeoVax Labs | n/m |
| ONCOOnconetix | −$199.38 |
| Peer median | −$207.09 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Sunshine Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.